SCHEMBL30144155

SCHEMBL30144155

C[C@H]1CN(C(=O)OCc2ccccc2)CCN1CCN1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.52
PDK2 Q15119 1/20 0.52
PDK3 Q15120 1/20 0.52
PDK4 Q16654 1/20 0.52
PARP1 P09874 1/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
HTT P42858 1/20 0.45
CYP2C19 P33261 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29927443 0.89 PDK1 (0.48) PDK1PDK2PDK3PDK4PARP1
SCHEMBL29132198 0.88 MEN1 (0.58) PARP1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL29927363 0.88 PDK1 (0.50) PDK1PDK2PDK3PDK4PARP1
SCHEMBL29927665 0.86 PDK1 (0.50) PDK1PDK2PDK3PDK4PARP1
SCHEMBL30706191 0.85 PDK1 (0.51) PDK1PDK2PDK3PDK4PARP1
SCHEMBL26927558 0.85 PDK1 (0.51) PDK1PDK2PDK3PDK4PARP1
SCHEMBL30731906 0.85 PDK1 (0.51) PDK1PDK2PDK3PDK4PARP1
SCHEMBL30706025 0.85 PDK1 (0.51) PDK1PDK2PDK3PDK4PARP1
SCHEMBL29927532 0.85 PDK1 (0.52) PDK1PDK2PDK3PDK4PARP1
SCHEMBL29928044 0.85 HTR2C (0.50) PDK1PDK2PDK3PDK4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697990-B Indazole-based compounds and related methods of use 阿维纳斯企业公司 2025-06-13 CN disclosed
US-20250114356-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2025-04-10 US disclosed
US-12053469-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-08-06 US disclosed
EP-4121422-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2023-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114356-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885
US-12053469-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.